Cellular immune responses and viral diversity in individuals treated during acute and early HIV-1 infection

Journal of Experimental Medicine

Volumn 193, Issue 2, 2001, Pages 169-180

  Altfeld, Marcus ^a   Rosenberg, Eric S ^a   Shankarappa, Raj ^d   Mukherjee, Joia S ^a   Hecht, Frederick M ^c   Eldridge, Robert L ^a   Addo, Marylyn M ^a   Poon, Samuel H ^a   Phillips, Mary N ^a   Robbins, Gregory K ^a   Sax, Paul E ^e   Boswell, Steve ^f   Kahn, James O ^b,c   Brander, Christian ^a   Goulder, Philip J R ^a   Levy, Jay A ^b   Mullins, James I ^d   Walker, Bruce D ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d UNIVERSITY OF WASHINGTON   (United States)

^e BRIGHAM AND WOMEN S HOSPITAL   (United States)

^f FENWAY INSTITUTE   (United States)

Author keywords

Cytotoxic T lymphocyte epitopes; Cytotoxic T lymphocytes; Human leukocyte antigen; T helper cell responses; Viral evolution

Indexed keywords

ANTIRETROVIRUS AGENT; EPITOPE; LEUKOCYTE ANTIGEN; PROTEINASE INHIBITOR; RNA DIRECTED DNA POLYMERASE INHIBITOR;

ARTICLE; CELLULAR IMMUNITY; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; FEMALE; HELPER CELL; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE RESPONSE; MALE; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; SEROCONVERSION; VIREMIA; VIRUS LOAD;

ACUTE DISEASE; AMINO ACID SEQUENCE; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; BASE SEQUENCE; COHORT STUDIES; DNA PRIMERS; EPITOPES; FEMALE; HIV INFECTIONS; HIV SEROPOSITIVITY; HIV-1; HUMANS; IMMUNITY, CELLULAR; LONGITUDINAL STUDIES; MALE; MOLECULAR SEQUENCE DATA; RNA, VIRAL; T-LYMPHOCYTES, CYTOTOXIC; T-LYMPHOCYTES, HELPER-INDUCER; TIME FACTORS; VARIATION (GENETICS);

EID: 0035862330     PISSN: 00221007     EISSN: None     Source Type: Journal    
DOI: 10.1084/jem.193.2.169     Document Type: Article

References (60)

1. + T helper cells in the cytotoxic T lymphocyte response to HIV-1
2. T lymphocyte responses in HIV-1 infection: Implications for vaccine development
3. Anti-HIV cellular immunity: Recent advances towards vaccine design
4. + cytotoxic T-lymphocyte activity associated with control of viremia in primary human immunodeficiency virus type 1 infection
5. Temporal association of cellular immune responses with the initial control of viremia in primary human immunodeficiency virus type 1 syndrome
6. + T cells with a predominant V beta usage during the primary immune response to HIV
7. + cells: Evidence for HLA class I-restricted triggering of cytolytic and noncytolytic mechanisms
8. Strong cytotoxic T cell and weak neutralizing antibody responses in a subset of persons with stable nonprogressing HIV type 1 infection
9. Cytotoxic T lymphocytes in asymptomatic long-term nonprogressing HIV-1 infection. Breadth and specificity of the response and relation to in vivo viral quasispecies in a person with prolonged infection and low viral load
10. Quantitation of HIV-1-specific cytotoxic T lymphocytes and plasma load of viral RNA
11. Kinetics of Gag-specific cytotoxic T lymphocyte responses during the clinical course of HIV-1 infection: A longitudinal analysis of rapid progressors and long-term asymptomatics
12. High levels of anti-human immunodeficiency virus type 1 (HIV-1) memory cytotoxic T-lymphocyte activity and low viral load are associated with lack of disease in HIV-1-infected long-term nonprogressors
13. Quantitative analysis of the human immunodeficiency virus type 1 (HIV-1)-specific cytotoxic T lymphocyte (CTL) response at different stages of HIV-1 infection: Differential CTL responses to HIV-1 and Epstein-Barr virus in late disease
14. + T cell depletion in simian immunodeficiency virus-infected macaques
15. + lymphocytes
16. Persistent infection of baboons and rhesus monkeys with different strains of HIV-2
17. + cytotoxic T-cell responses during chronic viral infection
18. + T-cell-deficient mice
19. CD4-deficient mice have reduced levels of memory cytotoxic T lymphocytes after immunization and show diminished resistance to subsequent virus challenge
20. + T cell responses associated with control of viremia
21. Association between virus-specific cytotoxic T-lymphocyte and helper responses in human immunodeficiency virus type 1 infection
22. The critical need for CD4 help in maintaining effective cytotoxic T lymphocyte responses
23. + T lymphocytes
24. Early and persistent human immunodeficiency virus type 1 (HIV-1)-specific T helper dysfunction in blood and lymph nodes following acute HIV-1 infection
25. Late escape from an immunodominant cytotoxic T-lymphocyte response associated with progression to AIDS
26. Positive selection of HIV-1 cytotoxic T lymphocyte escape variants during primary infection
27. Antiviral pressure exerted by HIV-1-specific cytotoxic T lymphocytes (CTLs) during primary infection demonstrated by rapid selection of CTL escape virus
28. Virus-specific cytotoxic T-lymphocyte responses select for amino-acid variation in simian immunodeficiency virus Env and Nef
29. The great escape - AIDS viruses and immune control
30. Human immunodeficiency virus type 1 evolution in vivo tracked by DNA heteroduplex mobility assays
31. Slower evolution of human immunodeficiency virus type 1 quasispecies during progression to AIDS
32. Intrahost human immunodeficiency virus type 1 evolution is related to length of the immunocompetent period
33. HIV-1 evolution and disease progression
34. Control of HIV despite the discontinuation of antiretroviral therapy
35. Consistent viral evolutionary changes associated with the progression of human immunodeficiency virus type 1 infection
36. The outcome of acute hepatitis C predicted by the evolution of the viral quasispecies
37. New testing strategy to detect early HIV-1 infection for use in incidence estimates and for clinical and prevention purposes
38. Comprehensive, serologically equivalent DNA typing for HLA-B by PCR using sequence-specific primers (PCR-SSP)
39. HIV-specific cytotoxic T lymphocytes in seropositive individuals
40. Long-term culture and fine specificity of human cytotoxic T-lymphocyte clones reactive with human immunodeficiency virus type 1
41. HIV-1 gag-specific cytotoxic T lymphocytes recognize multiple highly conserved epitopes. Fine specificity of the gag-specific response defined by using unstimulated peripheral blood mononuclear cells and cloned effector cells
42. Recent advances in HIV-1 CTL epitope characterization
43. Identification of dominant optimal HLA-B60- and HLA-B61-restricted cytotoxic T-lymphocyte (CTL) epitopes: Rapid characterization of CTL responses by enzyme-linked immunospot assay
44. Differential narrow focusing of immunodominant human immunodeficiency virus gag-specific cytotoxic T-lymphocyte responses in infected african and caucasoid adults and children
45. HIV quasispecies and resampling
46. Quantitation of target molecules from polymerase chain reaction-based limiting dilution assays
47. Genetic relationships determined by a DNA heteroduplex mobility assay: Analysis of HIV-1 env genes
48. Immune control of HIV-1 after early treatment of acute infection
49. + cell decline in HIV type 2-infected macaques
50. Analysis of a successful immune response against hepatitis C virus
51. Analysis of successful immune responses in persons infected with hepatitis C virus
52. + T-cell effector activity in HIV primary infection
53. Patterns of immunodominance in HIV-1-specific cytotoxic T lymphocyte responses in two human histocompatibility leukocyte antigens (HLA)-identical siblings with HLA-A*0201 are influenced by epitope mutation
54. Lack of strong immune selection pressure by the immunodominant HLA-A*0201-restricted cytotoxic T lymphocyte response in chronic human immunodeficiency virus-1 infection
55. + T cells in individuals receiving highly active antiretroviral therapy (HAART)
56. Biphasic kinetics of peripheral blood T cells after triple combination therapy in HIV-1 infection: A composite of redistribution and proliferation
57. + lymphocytes after HIV antiretroviral therapy reflects redistribution from lymphoid tissues
58. Decay kinetics of human immunodeficiency virus-specific effector cytotoxic T lymphocytes after combination antiretroviral therapy
59. Levels of human immunodeficiency virus type 1-specific cytotoxic T-lymphocyte effector and memory responses decline after suppression of viremia with highly active antiretroviral therapy